Our recent expansion to a new state-of-the-art facility has allowed us to further expand our R&D efforts as well as provide improved support services to clients seeking validated cell therapy development processes – from bioassay development through product development, validated raw materials and scale up.
With new innovative products and solutions, we will be attending the ISCT Annual Meeting in Las vegas this week presenting the latest developments and offerings from Akron.
- Human Plasma Fibronectin: On the heels of one of the most-trusted fibronectin products on the market – our research grade fibronectin – we will be announcing the launch of our GMP-grade fibronectin, including the industry-first virus-inactivated GMP fibronectin. We will be presenting the various formulation options as well as custom delivery solutions including coating services and well as bioassay services with a variety of cell lines.
- DMSO-Free Cyropreservation: Akron’s line of DMSO-free cryopreservation media, CryoNovo, is an ever-expanding line of cryopreservation media that is being developed under the mantra “one size doesn’t fit all.” In the spirit of this, we will be on hand to discuss options for cryopreserving traditionally hard-to-preserve cells as well as new developments in DMSO-free crypreservaton that address known difficulties encountered with various cell lines.
- AB Serum: Akron’s AB serum is true off-the clot: visit us at our booth to learn how our superior AB serum product can help you in your cell culture projects where other AB sera have failed.
- Custom Development Services: Bioassay development, cell therapy projuct validation, raw materials: innovations at Akron are constantly ongoing. Come to booth 412 to learn much more about how Akron is leading the way.
Here is a breakdown of opportunities to meet us and hear from us:
- Booth 412: We will be there throughout the conference, so make sure to come and speak with us
- Poster 259: Come learn about the latest in DMSO-free cryopreservation media. The poster session is Friday, May 29th from 5:30 – 7 pm
- Panel: Strategies for Commercialization Track 2 – Ancillary Materials. Dr. Claudia Zylberberg will chair, alongside Lynn Csontos, a panel discussion on ancillary materials on Thursday, May 28th from 11:15 – 12:30 in the Pompeian Ballroom I/II.
- Talk: Critical Considerations for the Development of Cell Therapy Potency Assays. Case study: Angiogenesis. Dr. Claudia Zylberberg will speak on Thursday, May 28 during the Strategies for Commercialization Track from 4 – 5:30 pm in the Pompeian Ballroom I/II.
If you would like to set up a private meeting, please contact us at firstname.lastname@example.org.